Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Antidiabetes Drug Makes Lung Cancer Susceptible to Radiotherapy

By BiotechDaily International staff writers
Posted on 28 May 2013
Metformin, an anitdiabetic drug, has been shown to slow the growth of lung cancer cells and makes them more likely to be killed by radiotherapy.

Scientists from McMaster University (Hamilton, ON, Canada) discovered that metformin acted on the defense mechanisms non-small-cell lung tumors—the most typical form of the disease—use to resist radiotherapy. They published their findings April 30, 2013, in the British Journal of Cancer.

Lung cancer cells typically adapt to radiotherapy by activating survival processes that make them resistant to the treatment and even helps them to grow faster. However, by examining lung cancer cells grown in the lab and in mice, the researchers showed that metformin reverses this effect, once again making them sensitive to radiotherapy. Significantly, the researchers utilized “real life” levels of the drug in their experiments, similar to those already used for treating diabetes.

Metformin seems to work by enhancing the damage-detection signals sent within cancer cells in response to radiotherapy, over-riding the cells’ survival mechanisms. These signals blocks cancer cells from producing the new proteins they need to grow rapidly, prevents them from making new cells and eventually encourages them to die.

Dr. Theodoros Tsakiridis, study author and a radiation oncologist at the Juravinski Cancer Center and McMaster University, said, “Our study shows that the diabetes drug metformin can stop lung cancer cells from growing and makes them more sensitive to treatment by radiotherapy. “We’re now working with other institutions to develop a clinical trial that will investigate metformin in lung cancer patients treated with radiotherapy. If we can prove that this works in patients then we could have a potentially powerful weapon in the fight against the disease.”

In spite radiotherapy being an effective treatment for many cancers, it has a limited effect for lung cancer patients. Dr. Kat Arney, science information manager at Cancer Research UK (London, UK), said, “Lung cancer remains one of the most difficult cancers to treat, with less than 10% of people surviving the disease for at least five years. We urgently need new and better ways of treating lung cancer and this research takes us a step towards making radiotherapy a more potent treatment. To improve the chances for lung cancer patients, Cancer Research UK is planning to increase significantly its investment in research into this form of the disease, so that patients can benefit from new and improved treatments sooner.”

Related Links:

McMaster University



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.